Abstract
Mesenchymal stem/stromal cells (MSCs) are in numerous cell therapy clinical trials, including for injured myocardium. Acquisition of cardiomyocyte characteristics by MSCs may improve cardiac regeneration but the mechanisms regulating this process are unclear. Here, we investigated whether the pluripotency transcription factor OCT4 is involved in the activation of cardiac lineage genetic programs in MSCs. We employed our established co-culture model of MSCs with rat embryonic cardiomyocytes showing co-expression of cardiac markers on MSCs independent of cell fusion. Bone marrow-derived MSCs were isolated from transgenic mice expressing GFP under the control of the cardiac-specific α-myosin heavy chain promoter. After 5 days of co-culture, MSCs expressed cardiac specific genes, including Nkx2.5, atrial natriuretic factor and α-cardiac actin. The frequency of GFP+ cells was 7.6±1.9%, however, these cells retained the stromal cell phenotype, indicating, as expected, only partial differentiation. Global OCT4 expression increased 2.6±0.7-fold in co-cultured MSCs and of interest, 87±5% vs 79±4% of MSCs expressed OCT4 by flow cytometry in controls and after co-culture, respectively. Consistent with the latter observation, the GFP+ cells did not express nuclear OCT4 and showed a significant increase in OCT4 promoter methylation compared with undifferentiated MSCs (92% vs 45%), inferring that OCT4 is regulated by an epigenetic mechanism. We further showed that siRNA silencing of OCT4 in MSCs resulted in a reduced frequency of GFP+ cells in co-culture to less than 1%. Our data infer that OCT4 expression may have a direct effect on partial cardiomyocyte reprogramming of MSCs and suggest a new mechanism(s) associated with MSC multipotency and a requirement for crosstalk with the cardiac microenvironment.
Highlights
Multipotent mesenchymal stromal cells (MSCs) can be obtained from different tissue sources including bone marrow (BM), adipose tissue and umbilical cord [1,2,3]
Paracrine action of MSCs, rather than direct regeneration by differentiation into cardiomyocytes, more likely explains the hemodynamic improvement as engraftment in the host myocardium is not required [13,14,15,16]. Consistent with this notion, we found that BM-derived MSCs acquire cardiac specific markers but retain MSCs properties when co-cultured with rat embryonic cardiomyocytes (RECs) [17]
We found that MSCs derived from the perivascular tissue of the umbilical cord (HUCPVCs) exhibit a greater degree of cardiomyocyte reprogramming than do BM-MSCs and provide improved cardiac function in an acute myocardial infarction (AMI) model after intra-myocardial injection [22] but not when administered systemically [15]
Summary
Multipotent mesenchymal stromal cells (MSCs) can be obtained from different tissue sources including bone marrow (BM), adipose tissue and umbilical cord [1,2,3]. We found that MSCs derived from the perivascular tissue of the umbilical cord (HUCPVCs) exhibit a greater degree of cardiomyocyte reprogramming than do BM-MSCs and provide improved cardiac function in an AMI model after intra-myocardial injection [22] but not when administered systemically [15]. These data infer a link between partial cardiomyocyte reprogramming and cardiac regenerative potential, as HUCPVCs showed improved benefit compared with BM-MSCs only when donor cells located mainly in the infarct area. The biological characteristics of the neonatal origin of HUCPVC tissue may position OCT4 as a key factor in mediating MSCs multipotency
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.